Volunteers With Dry Eye Sought for Clinical Trial to Evaluate Safety and Efficacy of Thymosin Beta 4 Ophthalmic Solution to Treat Dry Eye

August 15, 2011

Today, RegeneRx Biopharmaceuticals announced the commencement of a Phase 2 clinical trial to evaluate the safety and efficacy of the company’s preservative-free Thymosin Beta 4 eye drops (referred by the company as RGN-259 eye drops) in alleviating signs and symptoms of dry eye.

As its primary measures, the trial will look at the number of patients with decreased corneal staining, and decreased ocular discomfort following administration of the eye drops.

To learn more about the clinical trial, read the company’s press release and description of the trial on ClinicalTrials.gov.




Jump down to form below to submit your own comments

Comments are closed.